- Home
- AIXC vs IGC Comparison
AIXC vs IGC Comparison
Compare AIXC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIXC | IGC |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 30.0M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | AIXC | IGC |
|---|---|---|
| Price | $1.29 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.25 |
| AVG Volume (30 Days) | 41.4K | ★ 498.9K |
| Earning Date | 05-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.24 |
| 52 Week High | $2.98 | $0.50 |
Technical Indicators
Market Signals| Indicator | AIXC | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 51.51 |
| Support Level | $1.18 | $0.28 |
| Resistance Level | $1.48 | $0.31 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 38.71 | 58.71 |
Price Performance
Historical ComparisonAbout AIXC AIxCrypto Holdings Inc.
AIxCrypto Holdings Inc is a technology infrastructure company focused on the convergence of artificial intelligence and blockchain-based programmable systems. The Company develops software platforms and programmable infrastructure designed to facilitate the tokenization of real-world assets (RWA) and the deployment of Embodied Artificial Intelligence (EAI) in commercial environments. Its mission is to serve as the regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.